Close Menu

NEW YORK (GenomeWeb) – Genomic Health reported today that its fourth quarter revenues rose 6 percent year over year, with sharper growth in international sales and prostate cancer testing than in the company's core US breast cancer market.

For the three months ended Dec. 31, 2017, Genomic Health's total revenues were $87.5 million compared to $82.7 million in the same period last year, missing the consensus Wall Street estimate of $88.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.